Rice Hall James & Associates LLC Acquires Shares of 54,116 Medpace Holdings, Inc. $MEDP

Rice Hall James & Associates LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 54,116 shares of the company’s stock, valued at approximately $28,659,000. Medpace comprises about 1.4% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 15th biggest holding.

Other hedge funds have also made changes to their positions in the company. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new position in Medpace in the fourth quarter valued at about $30,000. Allied Private Wealth LLC bought a new stake in Medpace during the second quarter worth about $31,000. Basecamp Wealth Advisors LLC grew its stake in Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Medpace during the second quarter worth approximately $34,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Up 3.2%

Shares of MEDP opened at $597.12 on Tuesday. The stock’s fifty day simple moving average is $539.02 and its 200-day simple moving average is $491.54. The firm has a market capitalization of $16.67 billion, a PE ratio of 35.00, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 458 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total transaction of $274,978.62. Following the completion of the sale, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at $362,622,351.42. The trade was a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 67,195 shares of company stock worth $37,989,998 in the last 90 days. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on MEDP. TD Cowen lifted their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Finally, Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.